Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
myotonic dystrophy Type 1
Biotech
Sarepta shares safety update on DM1 RNA med
A drug safety group has delivered a positive review for an investigational siRNA being studied in a phase 1/2 trial for type 1 myotonic dystrophy.
Gabrielle Masson
Nov 24, 2025 4:00pm
PepGen ends all DMD work after phase 2 trial falls flat
May 28, 2025 5:30pm
RNA-targeting drug relaxes muscles in myotonic dystrophy mice
Dec 4, 2024 7:00am
Novartis signs $1.1B deal for muscular dystrophy biotech
Nov 21, 2024 8:19am
PepGen gains a little pep in its step as FDA clears trial hold
Oct 12, 2023 7:00am
Awaiting FDA letter, PepGen oligonucleotide no closer to clinic
Jun 14, 2023 9:05am
